# Graves' Disease Remission Study: MycoMeth Combo

> **NCT06068179** · PHASE2,PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 205 (estimated)

## Conditions studied

- Graves' Disease

## Interventions

- **DRUG:** Mycophenolate Mofetil, Oral, 250 Mg
- **DRUG:** methimazole, oral, 10mg

## Key facts

- **NCT ID:** NCT06068179
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-16
- **Primary completion:** 2025-10-08
- **Final completion:** 2026-10-08
- **Target enrollment:** 205 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068179, "Graves' Disease Remission Study: MycoMeth Combo". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06068179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*